A Phase I Clinical Trial to Evaluate the Safety of a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Administered to Healthy, HIV-1 Uninfected, Adult Participants Who Received DNA Plasmid Vaccine or Placebo in the HVTN 052 Clinical Trial
Latest Information Update: 16 Oct 2021
At a glance
- Drugs VRC-HIVADV014-00-VP (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 31 Mar 2015 New trial record